Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Laxmi Dental Ltd. (LAXMIDENTL.NS)
Mumbai, IN
Laxmi Dental Limited operates as a global manufacturer and supplier of diverse dental products, serving markets across India, the United States, the United Kingdom, and beyond. Its comprehensive portfolio includes personalized crowns, bridges, transparent orthodontic aligners, thermoforming materials, related aligner accessories, and specialized items for pediatric dentistry. The company caters to a broad clientele, encompassing dental clinics, dental enterprises, and individual practitioners. Headquartered in Mumbai, India, the firm was established in 2004.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.35% | -10.92% | +16.86% | +20.81% | -16.21% | -14.44% | -39.40% | -57.76% | -57.76% | -57.76% | -57.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+17.5% ★ Q1'26: +21.9% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-13.1% Q1'26: +137.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-6.8% Q1'26: -34.9% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+9.9% Q1'26: +12.3% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+16.6% ★ Q1'26: +22.7% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+5.0% Q1'26: -1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.30× ★ Q1'26: 0.24× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 1 Rev. Ana. 3 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|
| Revenue |
2.37B
est: 2.42B (-2.3%)
|
2.77B
2.76B – 2.78B
+14.3% YoY
|
3.34B
3.25B – 3.50B
+20.6% YoY
|
4.01B
3.82B – 4.36B
+20.1% YoY
|
| EBITDA |
522.20M
est: 534.42M (-2.3%)
|
610.87M
608.77M – 612.98M
+14.3% YoY
|
736.51M
717.17M – 772.72M
+20.6% YoY
|
884.52M
842.50M – 963.17M
+20.1% YoY
|
| EBIT |
372.01M
est: 380.72M (-2.3%)
|
435.18M
433.68M – 436.68M
+14.3% YoY
|
524.69M
510.90M – 550.48M
+20.6% YoY
|
630.13M
600.19M – 686.15M
+20.1% YoY
|
| Net Income |
317.71M
est: 296.45M (+7.2%)
|
393.51M
386.73M – 400.30M
+32.7% YoY
|
561.41M
498.58M – 668.83M
+42.7% YoY
|
708.32M
625.33M – 868.52M
+26.2% YoY
|
| SGA |
283.25M
est: 289.88M (-2.3%)
|
331.35M
330.21M – 332.49M
+14.3% YoY
|
399.50M
389.00M – 419.14M
+20.6% YoY
|
479.78M
456.99M – 522.44M
+20.1% YoY
|
| EPS |
6.07
est: 5.65 (+7.4%)
|
7.50
7.37 – 7.63
+32.7% YoY
|
10.70
9.50 – 12.75
+42.7% YoY
|
13.50
11.92 – 16.55
+26.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Goldman Sachs India Equity ETF GIND | 0.08% | 131.2K | 0.75% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rajesh Vrajlal Khakhar | Executive Chairperson & Whole-Time Director | 8M | male |
| Sameer Kamlesh Merchant | MD, Chief Executive Officer & Executive Director | 8M | male |
| Amrish Mahendrabhai Desai | Vice President and Head of Operations of USA & India | — | male |
| Dharmesh Bhupendra Dattani | Chief Financial Officer | — | male |
| Sarfaraz Nasir Merchant | Vice President & Head of Operations of Domestic Dental Laboratory | — | male |
| Suman Saha | Company Secretary & Compliance Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LAXMIDENTL.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
